Mineralys Therapeutics (MLYS) Income from Continuing Operations (2022 - 2026)
Mineralys Therapeutics (MLYS) reported Income from Continuing Operations of 45340000.0 for Q1 2026, down 2.01% on a YoY basis from 46269618.86 in Q1 2025, and up 75.44% sequentially from 184601000.0 in Q4 2025.
Mineralys Therapeutics (MLYS) Income from Continuing Operations (2022 - 2026) Analysis & Trends
Mineralys Therapeutics (MLYS) has 5 years of Income from Continuing Operations data on file, last reported at 45340000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 2.01% year-over-year to 45340000.0; the trailing twelve-month figure through Mar 2026 stood at 317818000.0 (down 12.93% YoY), and the FY2025 full-year result was 316925000.0, down 16.37% from the prior year.
- Income from Continuing Operations rose to 45340000.0 in Q1 2026, from 184601000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 6479000.0 in Q2 2022 to a low of 184601000.0 in Q4 2025.
- A 5-year average of 45126529.41 and a median of 35362000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations tumbled 360.99% in 2024 and surged 31.57% in 2025, its largest moves.
- Tracing MLYS's Income from Continuing Operations over 5 years: stood at 25569000.0 in 2022, then declined by 11.73% to 28568000.0 in 2023, then plunged by 360.99% to 131696000.0 in 2024, then plunged by 40.17% to 184601000.0 in 2025, then surged by 75.44% to 45340000.0 in 2026.
- Business Quant data shows MLYS's Income from Continuing Operations at 45340000.0 in Q1 2026, 184601000.0 in Q4 2025, and 41131000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Mineralys Therapeutics | 2.24 Bn | 2.24 Bn | - | -45.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -45.34 Mn |
| Dec 31, 2025 | -184.60 Mn |
| Sep 30, 2025 | -41.13 Mn |
| Jun 30, 2025 | -46.75 Mn |
| Mar 31, 2025 | -44.45 Mn |
| Dec 31, 2024 | -131.70 Mn |
| Sep 30, 2024 | -60.11 Mn |
| Jun 30, 2024 | -45.17 Mn |
| Mar 31, 2024 | -35.36 Mn |
| Dec 31, 2023 | -28.57 Mn |
| Sep 30, 2023 | -26.27 Mn |
| Jun 30, 2023 | -15.74 Mn |
| Mar 31, 2023 | -14.94 Mn |
| Dec 31, 2022 | -25.57 Mn |
| Sep 30, 2022 | -7.42 Mn |
| Jun 30, 2022 | -6.48 Mn |
| Mar 31, 2022 | -7.57 Mn |